UBS’s Alimera Sciences ALIM Stock Holding History

UBS’s Portfolio ALIM Stock Details ALIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$21K	Buy	260 +93	+56%	+$7.94K	﹤0.01%	7970
2014 Q2	$15K	Buy	167 +154	+1,185%	+$13.7K	﹤0.01%	8447
2014 Q1	$2K	Buy	+13	New	+$1.26K	﹤0.01%	10074

Other funds holding ALIM

Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS's ALIM Position: Q3 2014 in Review

UBS sold out of Alimera Sciences (ALIM) in Q3 2014, closing a stake of 75 shares — an estimated $6.41K sold.

UBS first reported a position in ALIM in Q2 2013 and held it in 4 quarters. The position peaked at $30K in Q2 2013. 60 funds tracked by Wall St. Rank hold ALIM as of Q3 2014.

UBS reported no remaining Alimera Sciences position as of Q3 2014 after selling out during the quarter.
UBS sold 75 Alimera Sciences shares in Q3 2014, an estimated $6.41K.
UBS first reported a position in Alimera Sciences in Q2 2013 and held it in 4 quarters.
UBS's Alimera Sciences position peaked at $30K in Q2 2013.
60 funds tracked by Wall St. Rank held Alimera Sciences as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.